Beyondspring

BYSI · NASDAQ

$0.5227+$0.0098 (+1.91%)TodayMarket closed ·
Prev close $0.5129

Latest news

  • Press releaseGlobe Newswire

    BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    BeyondSpring Files 2025 Annual Report on Form 10-K

  • Press releaseGlobe Newswire

    BeyondSpring Reports 2025 Year-End Financial Results

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • NewsAvi Kapoor

    Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

  • Press releaseGlobe Newswire

    BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

  • Press releaseGlobe Newswire

    BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    BeyondSpring Files 2024 Annual Report on Form 10-K

  • Press releaseGlobe Newswire

    BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.